Genevieve is responsible for developing and running our pre-clinical assays, and designs our DNA molecules. She is also ensuring smooth progress of our human cytomegalovirus (CMV) vaccine candidate to clinical trial.
An expert molecular biologist, Genevieve joined SpyBiotech in July 2017 from a post-doctoral position at the University of Oxford’s Jenner Institute where she worked on malaria vaccines. Her earlier carrier focused on the development of genetically-modified mosquitoes for pesticide-free pest control and reduction of mosquito-borne diseases, as part of the Oxitec biotech company.
Genevieve holds a PhD from Imperial College London in Molecular Entomology.